Tests nebulised RESP30TB with standard drugs for lung tuberculosis
Tests a nebulised drug added to standard treatment in adults with new lung tuberculosis.
Key facts
- Who runs it
- Thirty Respiratory Limited
- Where
- Cape Town, South AfricaSee the site
- Trial code
- Registry title
- Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 13 Oct 2025
- Planned end
- 15 Nov 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- RESP30TB
- HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
- Record updated
- 12 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with newly diagnosed lung tuberculosis that can be treated with rifampicin. It tests an inhaled (nebulised) drug called RESP30TB.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed pulmonary (lung) tuberculosis that is rifampicin susceptible, confirmed by molecular testing.
- Earlier treatment
- People cannot have had any drug active against M.tb for this episode of TB.
- Biomarker or test result
- Rifampicin susceptibility on molecular testing. Methaemoglobin saturation (SpMet) must not be above 3%. Lung function test FEV1 of 40% or more.
Main reasons for not taking part
- HIV positive with CD4 below 350 cells/mm3, or taking antiviral therapy (ART)
- Pregnant or breast-feeding women
- Taking part in another study with investigational agents within 8 weeks before screening
- Taking immunosuppressive medicines such as TNF-alpha inhibitors within 2 weeks before screening
- Taking NO or NO donor agents, phosphodiesterase inhibitors or lung surfactant drugs within 30 days before screening
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Provide written, informed consent prior to all trial-related procedures and agree to undergo all trial procedures
- Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
- Newly diagnosed pulmonary TB
- Rifampicin susceptible pulmonary TB as determined by molecular testing
- Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 mL or more)
- Spirometry performed during screening with a Forced Expiration Volume in the first second (FEV1) of ≥ 40%
- Be of non-childbearing potential or willing to use effective methods of contraception, as defined in section 4.3.4
Who cannot take part
- HIV positive AND CD4 < 350 cells/mm3 OR are receiving antiviral therapy (ART)
- Participation in other clinical studies with investigational agents within 8 weeks prior to screening
- Treatment received for this episode of TB with any drug active against M.tb
- Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening
- Treatment with NO and other NO donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening
- Baseline Methaemoglobin saturation (SpMet) >3%
- Female patients who is pregnant or breast-feeding
- Patients planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of IMP in the trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in South Africa.
- TASK Clinical Research CentreCape Town, South AfricaContact: Lukhanyile KeteloTaking people
About the trial
What the trial wants to find out
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
The 2 groups in the trial
- RESP30TBTreatment being tested
Stage 1 - Inhaled RESP30TB 6ml via nebulisation three times daily
- RESP30TB + HRZETreatment being tested
Stage 2 - Inhaled RESP30TB 6 ml dosed via nebulisation administered three times daily in combination with HRZE taken orally once daily
Treatment: RESP30TB and HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
- Plain-language title
- Tests nebulised RESP30TB with standard drugs for lung tuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07073638, who can take part
- Record updated
- 12 January 2026